Traws Pharma
Clinical-stage biopharmaceutical company developing oral small-molecule antivirals for respiratory viral diseases. The company advances investigational candidates targeting viral proteins (SARS-CoV-2 main protease and influenza cap‑dependent endonuclease), conducts Phase I clinical studies and preclinical challenge models, and uses accelerated clinical development strategies.
Industries
Nr. of Employees
medium (51-250)
Traws Pharma
Newtown, Pennsylvania, United States, North America
Patents
Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US-12156856-B2
View DetailsFormulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones
US-10098862-B1
View DetailsFormulations for parenteral administration of amino-substituted (E)-2, 6-dialkoxystyryl 4-substituted benzylsulfones
US-8476320-B2
View Details
Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US-12156856-B2
View DetailsFormulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones
US-10098862-B1
View DetailsFormulations for parenteral administration of amino-substituted (E)-2, 6-dialkoxystyryl 4-substituted benzylsulfones
US-8476320-B2
View DetailsProducts
Ratutrelvir (investigational oral Mpro inhibitor)
Investigational oral small-molecule inhibitor targeting the viral main protease (Mpro/3CL) being developed as a ritonavir‑independent treatment for COVID‑19/Long COVID; evaluated in Phase I for safety, tolerability, PK and PD.
Tivoxavir marboxil (investigational CEN inhibitor)
Investigational oral prodrug developed as a single‑dose treatment for seasonal and avian influenza; targets influenza cap‑dependent endonuclease and demonstrated safety, PK and protection in a rodent H5N1 challenge model in Phase I/preclinical data.
TRX01 (ratutrelvir)
An investigational high-potency MPro/3CL inhibitor developed for the treatment of COVID-19, designed to be administered without ritonavir and targeted for once-daily dosing over a 10-day regimen.
Ratutrelvir
An investigational oral small molecule antiviral targeting COVID-19 and Long COVID as a ritonavir-independent treatment.
Tivoxavir marboxil
An investigational oral small molecule antiviral in development as a single dose treatment for bird flu and seasonal influenza.
Rigosertib
A small molecule kinase inhibitor including PLK-1, offered as part of legacy clinical oncology programs seeking development and commercialization partners.
Ratutrelvir (investigational oral Mpro inhibitor)
Investigational oral small-molecule inhibitor targeting the viral main protease (Mpro/3CL) being developed as a ritonavir‑independent treatment for COVID‑19/Long COVID; evaluated in Phase I for safety, tolerability, PK and PD.
Tivoxavir marboxil (investigational CEN inhibitor)
Investigational oral prodrug developed as a single‑dose treatment for seasonal and avian influenza; targets influenza cap‑dependent endonuclease and demonstrated safety, PK and protection in a rodent H5N1 challenge model in Phase I/preclinical data.
TRX01 (ratutrelvir)
An investigational high-potency MPro/3CL inhibitor developed for the treatment of COVID-19, designed to be administered without ritonavir and targeted for once-daily dosing over a 10-day regimen.
Ratutrelvir
An investigational oral small molecule antiviral targeting COVID-19 and Long COVID as a ritonavir-independent treatment.
Tivoxavir marboxil
An investigational oral small molecule antiviral in development as a single dose treatment for bird flu and seasonal influenza.
Rigosertib
A small molecule kinase inhibitor including PLK-1, offered as part of legacy clinical oncology programs seeking development and commercialization partners.
Services
Preparation and dissemination of scientific posters and corporate/ investor decks at scientific conferences and investor events.
Preparation and dissemination of scientific posters and corporate/ investor decks at scientific conferences and investor events.
Expertise Areas
- Antiviral drug discovery (oral small molecules)
- Clinical development (Phase I)
- Virology and viral assay development
- Preclinical in vivo efficacy models
Key Technologies
- Small-molecule antiviral drug discovery
- Protease inhibition targeting viral Mpro/3CL
- Cap-dependent endonuclease (CEN) inhibition
- Preclinical rodent viral challenge models
News & Updates
Investor event held March 31, 2025; replay available.
Conference poster presenting Phase I safety, tolerability and pharmacokinetics of an influenza CEN inhibitor and preclinical protection data in a rodent challenge model.
Poster presenting Phase I safety, tolerability, pharmacokinetics and pharmacodynamics for a potent SARS‑CoV‑2 main protease inhibitor.
Company corporate presentation deck (November 2025).
Investor event held March 31, 2025; replay available.
Conference poster presenting Phase I safety, tolerability and pharmacokinetics of an influenza CEN inhibitor and preclinical protection data in a rodent challenge model.
Poster presenting Phase I safety, tolerability, pharmacokinetics and pharmacodynamics for a potent SARS‑CoV‑2 main protease inhibitor.
Company corporate presentation deck (November 2025).